A phase I study of SMP-105 (BCG-CWS) in patients with advanced cancers refractory to the standard treatment - A phase I study of SMP-105 (BCG-CWS)

Kobe Haborland Immunotherapy Clinic0 个研究点目标入组 9 人开始时间: 2012年7月25日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients with severe complications infectious disease, interstitial pneumonitis, cardiac disease, renal disease, hepatic disease, and uncontrolled diabetes mellitus. 2) Patients with autoimmune disease (scleroderma, Sjogren's syndrome syndrome, idiopathic thrombocytopenic purpura, multiple sclerosis, rheumatoid arthritis, and so on). 3) Patients who need the treatment with corticosteroids and immunesuppressive agents during this study (The use of their local and inhaled administration and non-steroidal anti-inflammatory agents is permitted). 4) Pregnant, lactating, or potentially to be pregnant. 5) Patients judged inappropriate for this study by responsible investigators.

发起方

Kobe Haborland Immunotherapy Clinic